Skip to main content
Avicanna Inc. logo

Avicanna Inc. — Investor Relations & Filings

Ticker · AVCN LEI · 254900AUQ4URGWO3FN90 TSX Manufacturing
Open in API
Filings indexed 291 across all filing types
Latest filing 2026-04-01 Audit Report / Informat…
Country CA Canada
Listing TSX AVCN

About Avicanna Inc.

https://www.avicanna.com/

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based, cannabinoid-based products for the global medical and pharmaceutical markets. The company operates through four commercial pillars: Medical Cannabis Products (RHO Phyto™), a Medical Cannabis Care Platform (MyMedi.ca), a Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients (Aureus Santa Marta™). Avicanna leverages an industry-leading scientific platform, including R&D collaborations with academic institutions and a robust IP portfolio, resulting in over 50 proprietary commercialized SKUs.

Recent filings

Filing Released Lang Actions
Audited annual financial statements (amended) - English.pdf
Audit Report / Information Classification · 1% confidence The document begins with an Independent Auditor’s Report, includes the auditor’s opinion, basis for opinion, emphasis of matters, key audit matters, and the audited consolidated financial statements (statements of financial position, operations, changes in equity, and cash flows) for the years ended December 31, 2025 and 2024. There is no broader narrative, MD&A, or strategic discussion typical of a full Annual Report (10-K). This is a standalone audit report and accompanying financial statements, matching the description of Audit Report / Information (AR). FY 2025
2026-04-01 English
Audited annual financial statements (amended) - English.pdf
Audit Report / Information Classification · 1% confidence The document consists of an Independent Auditor’s Report issued by RJ International CPAs, followed by the audited consolidated financial statements of Avicanna Inc. for the years ended December 31, 2025 and 2024. There is no full annual report context (e.g., MD&A, narrative sections, management letters) but rather a standalone audit opinion and financial statements package, which fits the definition of a standalone audit report. Therefore it should be classified as Audit Report / Information (Code: AR). FY 2025
2026-04-01 English
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a press release announcing the company’s full‐year 2025 audited financial statements and MD&A filing, providing key financial highlights (revenue, EBITDA, margins) and business updates, and scheduling an earnings call. It is not the full Annual Report nor just a publication notice; it fits the definition of an Earnings Release. FY 2025
2026-04-01 English
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a corporate news release titled “Avicenna Reports Full Year 2025 Audited Financial Statements” that summarizes audited full-year results, key financial highlights (revenue, adjusted EBITDA, margins), operational developments, and invites investors to an earnings call. It does not contain the full audited statement itself (nor the full annual report), but is clearly an initial announcement of periodical financial results. This matches the definition of an Earnings Release (ER). FY 2025
2026-04-01 English
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a corporate press release announcing full-year 2025 audited financial results with revenue, EBITDA, and operational highlights, and includes an invitation to an earnings call. It goes beyond merely stating that a report is available (which would be RPA) by providing key financial metrics and business commentary typical of an Earnings Release. Therefore, it should be classified as an Earnings Release (ER). FY 2025
2026-04-01 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 1% confidence The document is a Form 13-502F1 filed with the Ontario Securities Commission certifying market values and calculation of participation fees under OSC Rule 13-502. It is neither an earnings release, annual report, nor management discussion, but a regulatory fee filing. This falls under the fallback “Regulatory Filings” category.
2026-04-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.